IMF co-founders Susie and Brian Durie receive honorary doctorate from Vrije Univesiteit Brussel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

International Myeloma Foundation co-founder and president, Susie Durie, and Chairman Brian Durie were awarded a joint honorary doctorate for scientific excellence from the Vrije Universiteit Brussel at a ceremony in Brussels.

Honorary doctorates were also bestowed upon Swedish statistician Hans Rosling (given posthumously), French mathematics historian Karine Chemla, Belgian pioneering mathematician Freddy Van Oystaeyen, American mathematician and champion of better STEM education Padmanabhan Seshaiyer, Dutch physicist and science communicator Robbert Dijkgraaf, and political cartoonist Gerard Alsteens.

The university praised what its leadership called Durie’s “extraordinary” merit: “He is at the foundation of the development of new diagnostic and therapeutic possibilities, which have led to a significant increase in life expectancy following the diagnosis of multiple myeloma.” Together with Susie Durie, they founded the IMF “to inform patients and to involve them in the knowledge about their illness, but also to encourage doctors worldwide to work together to develop best practice guidelines.”

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login